Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Jennifer Ben Shimol x
  • All content x
Clear All Modify Search
Restricted access

Amanda Leiter, Emily Carroll, Sonia De Alwis, Danielle Brooks, Jennifer Ben Shimol, Elliot Eisenberg, Juan P Wisnivesky, Matthew D Galsky, and Emily Jane Gallagher

Objective

Obese and overweight body mass index (BMI) categories have been associated with increased immune-related adverse events (irAEs) in patients with cancer receiving immune checkpoint inhibitors (ICIs); however, the impact of being overweight in conjunction with related metabolic syndrome-associated factors on irAEs have not been investigated. We aimed to evaluate the impact of overweight and obese BMI according to metabolic disease burden on the development of irAEs.

Design and methods

We conducted a retrospective observational study of patients receiving ICIs at a cancer center. Our main study outcome was development of ≥grade 2 (moderate) irAEs. Our main predictor was weight/metabolic disease risk category: (1) normal weight (BMI 18.5–24.9 kg/m2)/low metabolic risk (<2 metabolic diseases (diabetes, dyslipidemia, hypertension)), (2) normal weight/high metabolic risk (≥2 metabolic diseases), (3) overweight (BMI ≥ 25 kg/m2)/low metabolic risk, and (4) overweight/high metabolic risk.

Results

Of 411 patients in our cohort, 374 were eligible for analysis. Overall, 111 (30%) patients developed ≥grade 2 irAEs. In Cox analysis, overweight/low metabolic risk was significantly associated with ≥grade 2 irAEs (hazard ratio (HR): 2.0, 95% confidence interval (95% CI): 1.2–3.4) when compared to normal weight/low metabolic risk, while overweight/high metabolic risk (HR: 1.3, 95% CI: 0.7–2.2) and normal weight/high metabolic risk (HR: 1.5, 95% CI: 0.7–3.0) were not.

Conclusions

Overweight patients with fewer metabolic comorbidities were at increased risk for irAEs. This study provides an important insight that BMI should be evaluated in the context of associated metabolic comorbidities in assessing risk of irAE development and ICI immune response.